Global Chemotherapy Induced Neutropenia Drug Market Insights, Forecast to 2025

1 Study Coverage

• 1.1 Chemotherapy Induced Neutropenia Drug Product Introduction
• 1.2 Market Segments
• 1.3 Key Chemotherapy Induced Neutropenia Drug Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Chemotherapy Induced Neutropenia Drug Market Size Growth Rate by Type
  • 1.4.2 F-627
  • 1.4.3 BBT-018
  • 1.4.4 Filgrastim
  • 1.4.5 GW-003
  • 1.4.6 NLA-101
  • 1.4.7 Others
• 1.5 Market by Application
  • 1.5.1 Global Chemotherapy Induced Neutropenia Drug Market Size Growth Rate by Application
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Chemotherapy Induced Neutropenia Drug Market Size, Estimates and Forecasts
  • 2.1.1 Global Chemotherapy Induced Neutropenia Drug Revenue 2015-2026
  • 2.1.2 Global Chemotherapy Induced Neutropenia Drug Sales 2015-2026
• 2.2 Global Chemotherapy Induced Neutropenia Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.2.1 Global Chemotherapy Induced Neutropenia Drug Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global Chemotherapy Induced Neutropenia Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Chemotherapy Induced Neutropenia Drug Competitor Landscape by Players

• 3.1 Chemotherapy Induced Neutropenia Drug Sales by Manufacturers
  • 3.1.1 Chemotherapy Induced Neutropenia Drug Sales by Manufacturers (2015-2020)
  • 3.1.2 Chemotherapy Induced Neutropenia Drug Sales Market Share by Manufacturers (2015-2020)
• 3.2 Chemotherapy Induced Neutropenia Drug Revenue by Manufacturers
  • 3.2.1 Chemotherapy Induced Neutropenia Drug Revenue by Manufacturers (2015-2020)
  • 3.2.2 Chemotherapy Induced Neutropenia Drug Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Chemotherapy Induced Neutropenia Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Chemotherapy Induced Neutropenia Drug Revenue in 2019
  • 3.2.5 Global Chemotherapy Induced Neutropenia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Chemotherapy Induced Neutropenia Drug Price by Manufacturers
• 3.4 Chemotherapy Induced Neutropenia Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Chemotherapy Induced Neutropenia Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Chemotherapy Induced Neutropenia Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Chemotherapy Induced Neutropenia Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Chemotherapy Induced Neutropenia Drug Market Size by Type (2015-2020)
  • 4.1.1 Global Chemotherapy Induced Neutropenia Drug Sales by Type (2015-2020)
  • 4.1.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2015-2020)
  • 4.1.3 Chemotherapy Induced Neutropenia Drug Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Chemotherapy Induced Neutropenia Drug Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Chemotherapy Induced Neutropenia Drug Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Chemotherapy Induced Neutropenia Drug Revenue Forecast by Type (2021-2026)
  • 4.2.3 Chemotherapy Induced Neutropenia Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Chemotherapy Induced Neutropenia Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global Chemotherapy Induced Neutropenia Drug Market Size by Application (2015-2020)
  • 5.1.1 Global Chemotherapy Induced Neutropenia Drug Sales by Application (2015-2020)
  • 5.1.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2015-2020)
  • 5.1.3 Chemotherapy Induced Neutropenia Drug Price by Application (2015-2020)
• 5.2 Chemotherapy Induced Neutropenia Drug Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Chemotherapy Induced Neutropenia Drug Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Chemotherapy Induced Neutropenia Drug Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Chemotherapy Induced Neutropenia Drug Price Forecast by Application (2021-2026)

6 North America

• 6.1 North America Chemotherapy Induced Neutropenia Drug by Country
  • 6.1.1 North America Chemotherapy Induced Neutropenia Drug Sales by Country
  • 6.1.2 North America Chemotherapy Induced Neutropenia Drug Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
• 6.3 North America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

7 Europe

• 7.1 Europe Chemotherapy Induced Neutropenia Drug by Country
  • 7.1.1 Europe Chemotherapy Induced Neutropenia Drug Sales by Country
  • 7.1.2 Europe Chemotherapy Induced Neutropenia Drug Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
• 7.3 Europe Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

8 Asia Pacific

• 8.1 Asia Pacific Chemotherapy Induced Neutropenia Drug by Region
  • 8.1.1 Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Region
  • 8.1.2 Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
• 8.3 Asia Pacific Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

9 Latin America

• 9.1 Latin America Chemotherapy Induced Neutropenia Drug by Country
  • 9.1.1 Latin America Chemotherapy Induced Neutropenia Drug Sales by Country
  • 9.1.2 Latin America Chemotherapy Induced Neutropenia Drug Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
• 9.3 Central & South America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

10 Middle East and Africa

• 10.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug by Country
  • 10.1.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country
  • 10.1.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Type
• 10.3 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Application

11 Company Profiles

• 11.1 BeyondSpring Pharmaceuticals Inc
  • 11.1.1 BeyondSpring Pharmaceuticals Inc Corporation Information
  • 11.1.2 BeyondSpring Pharmaceuticals Inc Description and Business Overview
  • 11.1.3 BeyondSpring Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.1.5 BeyondSpring Pharmaceuticals Inc Related Developments
• 11.2 Biocon Ltd
  • 11.2.1 Biocon Ltd Corporation Information
  • 11.2.2 Biocon Ltd Description and Business Overview
  • 11.2.3 Biocon Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 Biocon Ltd Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.2.5 Biocon Ltd Related Developments
• 11.3 Bolder Biotechnology Inc
  • 11.3.1 Bolder Biotechnology Inc Corporation Information
  • 11.3.2 Bolder Biotechnology Inc Description and Business Overview
  • 11.3.3 Bolder Biotechnology Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.3.5 Bolder Biotechnology Inc Related Developments
• 11.4 Cellerant Therapeutics Inc
  • 11.4.1 Cellerant Therapeutics Inc Corporation Information
  • 11.4.2 Cellerant Therapeutics Inc Description and Business Overview
  • 11.4.3 Cellerant Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.4.5 Cellerant Therapeutics Inc Related Developments
• 11.5 Chong Kun Dang Pharmaceutical Corp
  • 11.5.1 Chong Kun Dang Pharmaceutical Corp Corporation Information
  • 11.5.2 Chong Kun Dang Pharmaceutical Corp Description and Business Overview
  • 11.5.3 Chong Kun Dang Pharmaceutical Corp Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.5.5 Chong Kun Dang Pharmaceutical Corp Related Developments
• 11.6 Cinfa Biotech SL
  • 11.6.1 Cinfa Biotech SL Corporation Information
  • 11.6.2 Cinfa Biotech SL Description and Business Overview
  • 11.6.3 Cinfa Biotech SL Sales, Revenue and Gross Margin (2015-2020)
  • 11.6.4 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.6.5 Cinfa Biotech SL Related Developments
• 11.7 Dr. Reddy's Laboratories Ltd
  • 11.7.1 Dr. Reddy's Laboratories Ltd Corporation Information
  • 11.7.2 Dr. Reddy's Laboratories Ltd Description and Business Overview
  • 11.7.3 Dr. Reddy's Laboratories Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.7.4 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.7.5 Dr. Reddy's Laboratories Ltd Related Developments
• 11.8 Gene Techno Science Co Ltd
  • 11.8.1 Gene Techno Science Co Ltd Corporation Information
  • 11.8.2 Gene Techno Science Co Ltd Description and Business Overview
  • 11.8.3 Gene Techno Science Co Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.8.4 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.8.5 Gene Techno Science Co Ltd Related Developments
• 11.9 Generon (Shanghai) Corp Ltd
  • 11.9.1 Generon (Shanghai) Corp Ltd Corporation Information
  • 11.9.2 Generon (Shanghai) Corp Ltd Description and Business Overview
  • 11.9.3 Generon (Shanghai) Corp Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.9.4 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.9.5 Generon (Shanghai) Corp Ltd Related Developments
• 11.10 Genexine Inc
  • 11.10.1 Genexine Inc Corporation Information
  • 11.10.2 Genexine Inc Description and Business Overview
  • 11.10.3 Genexine Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.10.4 Genexine Inc Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.10.5 Genexine Inc Related Developments
• 11.1 BeyondSpring Pharmaceuticals Inc
  • 11.1.1 BeyondSpring Pharmaceuticals Inc Corporation Information
  • 11.1.2 BeyondSpring Pharmaceuticals Inc Description and Business Overview
  • 11.1.3 BeyondSpring Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Products Offered
  • 11.1.5 BeyondSpring Pharmaceuticals Inc Related Developments
• 11.12 Hanmi Pharmaceuticals Co Ltd
  • 11.12.1 Hanmi Pharmaceuticals Co Ltd Corporation Information
  • 11.12.2 Hanmi Pharmaceuticals Co Ltd Description and Business Overview
  • 11.12.3 Hanmi Pharmaceuticals Co Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.12.4 Hanmi Pharmaceuticals Co Ltd Products Offered
  • 11.12.5 Hanmi Pharmaceuticals Co Ltd Related Developments
• 11.13 Intas Pharmaceuticals Ltd
  • 11.13.1 Intas Pharmaceuticals Ltd Corporation Information
  • 11.13.2 Intas Pharmaceuticals Ltd Description and Business Overview
  • 11.13.3 Intas Pharmaceuticals Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.13.4 Intas Pharmaceuticals Ltd Products Offered
  • 11.13.5 Intas Pharmaceuticals Ltd Related Developments
• 11.14 Lupin Ltd
  • 11.14.1 Lupin Ltd Corporation Information
  • 11.14.2 Lupin Ltd Description and Business Overview
  • 11.14.3 Lupin Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.14.4 Lupin Ltd Products Offered
  • 11.14.5 Lupin Ltd Related Developments
• 11.15 Mycenax Biotech Inc
  • 11.15.1 Mycenax Biotech Inc Corporation Information
  • 11.15.2 Mycenax Biotech Inc Description and Business Overview
  • 11.15.3 Mycenax Biotech Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.15.4 Mycenax Biotech Inc Products Offered
  • 11.15.5 Mycenax Biotech Inc Related Developments
• 11.16 Myelo Therapeutics GmbH
  • 11.16.1 Myelo Therapeutics GmbH Corporation Information
  • 11.16.2 Myelo Therapeutics GmbH Description and Business Overview
  • 11.16.3 Myelo Therapeutics GmbH Sales, Revenue and Gross Margin (2015-2020)
  • 11.16.4 Myelo Therapeutics GmbH Products Offered
  • 11.16.5 Myelo Therapeutics GmbH Related Developments
• 11.17 Nohla Therapeutics Inc
  • 11.17.1 Nohla Therapeutics Inc Corporation Information
  • 11.17.2 Nohla Therapeutics Inc Description and Business Overview
  • 11.17.3 Nohla Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.17.4 Nohla Therapeutics Inc Products Offered
  • 11.17.5 Nohla Therapeutics Inc Related Developments
• 11.18 Octapharma AG
  • 11.18.1 Octapharma AG Corporation Information
  • 11.18.2 Octapharma AG Description and Business Overview
  • 11.18.3 Octapharma AG Sales, Revenue and Gross Margin (2015-2020)
  • 11.18.4 Octapharma AG Products Offered
  • 11.18.5 Octapharma AG Related Developments
• 11.19 Pangen Biotech Inc.
  • 11.19.1 Pangen Biotech Inc. Corporation Information
  • 11.19.2 Pangen Biotech Inc. Description and Business Overview
  • 11.19.3 Pangen Biotech Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 11.19.4 Pangen Biotech Inc. Products Offered
  • 11.19.5 Pangen Biotech Inc. Related Developments
• 11.20 Pfenex Inc
  • 11.20.1 Pfenex Inc Corporation Information
  • 11.20.2 Pfenex Inc Description and Business Overview
  • 11.20.3 Pfenex Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.20.4 Pfenex Inc Products Offered
  • 11.20.5 Pfenex Inc Related Developments
• 11.21 Pfizer Inc
  • 11.21.1 Pfizer Inc Corporation Information
  • 11.21.2 Pfizer Inc Description and Business Overview
  • 11.21.3 Pfizer Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.21.4 Pfizer Inc Products Offered
  • 11.21.5 Pfizer Inc Related Developments
• 11.22 Reliance Life Sciences Pvt Ltd
  • 11.22.1 Reliance Life Sciences Pvt Ltd Corporation Information
  • 11.22.2 Reliance Life Sciences Pvt Ltd Description and Business Overview
  • 11.22.3 Reliance Life Sciences Pvt Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.22.4 Reliance Life Sciences Pvt Ltd Products Offered
  • 11.22.5 Reliance Life Sciences Pvt Ltd Related Developments
• 11.23 Richter Gedeon Nyrt
  • 11.23.1 Richter Gedeon Nyrt Corporation Information
  • 11.23.2 Richter Gedeon Nyrt Description and Business Overview
  • 11.23.3 Richter Gedeon Nyrt Sales, Revenue and Gross Margin (2015-2020)
  • 11.23.4 Richter Gedeon Nyrt Products Offered
  • 11.23.5 Richter Gedeon Nyrt Related Developments
• 11.24 Sandoz International GmbH
  • 11.24.1 Sandoz International GmbH Corporation Information
  • 11.24.2 Sandoz International GmbH Description and Business Overview
  • 11.24.3 Sandoz International GmbH Sales, Revenue and Gross Margin (2015-2020)
  • 11.24.4 Sandoz International GmbH Products Offered
  • 11.24.5 Sandoz International GmbH Related Developments
• 11.25 USV Pvt Ltd
  • 11.25.1 USV Pvt Ltd Corporation Information
  • 11.25.2 USV Pvt Ltd Description and Business Overview
  • 11.25.3 USV Pvt Ltd Sales, Revenue and Gross Margin (2015-2020)
  • 11.25.4 USV Pvt Ltd Products Offered
  • 11.25.5 USV Pvt Ltd Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 Chemotherapy Induced Neutropenia Drug Market Estimates and Projections by Region
  • 12.1.1 Global Chemotherapy Induced Neutropenia Drug Sales Forecast by Regions 2021-2026
  • 12.1.2 Global Chemotherapy Induced Neutropenia Drug Revenue Forecast by Regions 2021-2026
• 12.2 North America Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
  • 12.2.1 North America: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
  • 12.2.2 North America: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
  • 12.2.3 North America: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2021-2026)
• 12.3 Europe Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
  • 12.3.1 Europe: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
  • 12.3.2 Europe: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
  • 12.3.3 Europe: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Region (2021-2026)
• 12.5 Latin America Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
  • 12.5.2 Latin America: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: Chemotherapy Induced Neutropenia Drug Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: Chemotherapy Induced Neutropenia Drug Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: Chemotherapy Induced Neutropenia Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter's Five Forces Analysis
• 13.5 Primary Interviews with Key Chemotherapy Induced Neutropenia Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Chemotherapy Induced Neutropenia Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details